PACMAN-AMI trial: review of endpoints

Česká verzia

Authors: Roman Margóczy ^1,2
Authors place of work: II. klinika kardiológie a angiológie, LF Slovenskej zdravotnickej univerzity, Bratislava ¹; Oddelenie funkčnej diagnostiky, Stredoslovenský ústav srdcových a cievnych chorôb, Banská Bystrica ²
Published in the journal: AtheroRev 2022; 7(3): 156-158
Category: Clinical Studies

Summary

Timely addition of alirocumab to high-intensity statin therapy in patients with myocardial infarction resulted in lipid profile improvement and significantly greater percent atheroma volume regression, assessed by combination of three intracoronary imaging modalities.

Keywords:

alirocumab – fibrous cap thickness (FCT) – intravascular ultrasonography (IVUS) – maximal lipid core burden index (maxLCBI) – near infrared spectroscopy (NIRS) – optical coherence tomography (OCT) – percent atheroma volume (PAV)

Zdroje

1. Räber L, Ueki Y, Otsuka T et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA 2022; 327(18): 1771–1781. Dostupné z DOI: <http://10.1001/jama.2022.5218>.